Literature DB >> 14678229

Role of angiotensin AT1 and AT2 receptors in cardiac hypertrophy and cardiac remodelling.

Yi-Chun Zhu1, Yi-Zhun Zhu, Ning Lu, Ming-Jie Wang, Yan-Xia Wang, Tai Yao.   

Abstract

1. Left ventricular hypertrophy (LVH) is an independent cardiovascular risk factor. Angiotensin AT1 receptor antagonism has been considered as a specific approach to block the renin-angiotensin system and been demonstrated to be able to prevent or regress LVH by interfering with the remodelling process of the heart. 2. Angiotensin AT1 receptor blockade induces a marked increase in angiotensin (Ang) II, which may stimulate the AT2 receptors. Gene expression of AT1 and AT2 receptors increases in a time-dependent manner in cardiac remodelling following myocardial infarction. 3. Considerable efforts have been made to clarify the role of AT2 receptors in cardiac hypertrophy and remodelling since the mid-1990s, resulting in controversial reports: the AT2 receptor mediates actions either opposite to or in coordination with those of the AT1 receptor. Moreover, there are many reports of no significant effects mediated by AT2 receptors. 4. Based on the studies reviewed in the present article, we assume that the predominant effect of AngII in cardiac hypertrophy and cardiac remodelling is growth promoting and that this effect is mediated mainly via AT1 receptors. The AT2 receptors may affect the hypertrophic process by interacting with other cardiac membrane proteins, enzymes and autacoids. Before coming to a conclusion as to whether AT2 receptor stimulation or antagonism is beneficial to the heart, more studies should be performed in different LVH models, especially long-term treatment protocols in vivo.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14678229     DOI: 10.1111/j.1440-1681.2003.03942.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  24 in total

Review 1.  Local renin-angiotensin systems in the genitourinary tract.

Authors:  Craig Comiter
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-11-13       Impact factor: 3.000

Review 2.  Connecting sex differences, estrogen signaling, and microRNAs in cardiac fibrosis.

Authors:  Lejla Medzikovic; Laila Aryan; Mansoureh Eghbali
Journal:  J Mol Med (Berl)       Date:  2019-08-26       Impact factor: 4.599

Review 3.  Healthful aging mediated by inhibition of oxidative stress.

Authors:  Stephen F Vatner; Jie Zhang; Marko Oydanich; Tolga Berkman; Rotem Naftalovich; Dorothy E Vatner
Journal:  Ageing Res Rev       Date:  2020-10-19       Impact factor: 10.895

4.  Angiotensin receptors alter myocardial infarction-induced remodeling of the guinea pig cardiac plexus.

Authors:  Jean C Hardwick; Shannon E Ryan; Emily N Powers; E Marie Southerland; Jeffrey L Ardell
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-05-06       Impact factor: 3.619

5.  Conditional expression of the type 2 angiotensin II receptor in mesenchymal stem cells inhibits neointimal formation after arterial injury.

Authors:  Jian Feng; Jian-Ping Liu; Li Miao; Guo-Xiang He; De Li; Hai-Dong Wang; Tao Jing
Journal:  J Cardiovasc Transl Res       Date:  2014-08-14       Impact factor: 4.132

6.  Heat shock protein 90 regulates IκB kinase complex and NF-κB activation in angiotensin II-induced cardiac cell hypertrophy.

Authors:  Kyung Hye Lee; Yangsoo Jang; Ji Hyung Chung
Journal:  Exp Mol Med       Date:  2010-10-31       Impact factor: 8.718

7.  Increased angiotensin II AT1 receptor mRNA and binding in spleen and lung of AT2 receptor gene disrupted mice.

Authors:  Jaroslav Pavel; José A Terrón; Julius Benicky; Alicia Falcón-Neri; Amita Rachakonda; Tadashi Inagami; Juan M Saavedra
Journal:  Regul Pept       Date:  2009-09-17

8.  The ontogeny of genes related to ovine fetal cardiac growth.

Authors:  Seth A Reini; Charles E Wood; Maureen Keller-Wood
Journal:  Gene Expr Patterns       Date:  2008-09-21       Impact factor: 1.224

9.  Lp-PLA2 inhibition prevents Ang II-induced cardiac inflammation and fibrosis by blocking macrophage NLRP3 inflammasome activation.

Authors:  Si-Lin Lv; Zi-Fan Zeng; Wen-Qiang Gan; Wei-Qi Wang; Tie-Gang Li; Yu-Fang Hou; Zheng Yan; Ri-Xin Zhang; Min Yang
Journal:  Acta Pharmacol Sin       Date:  2021-07-05       Impact factor: 6.150

10.  Cannabidiol-mediated RISK PI3K/AKT and MAPK/ERK pathways decreasing reperfusion myocardial damage.

Authors:  Antonio Franco-Vadillo; Mireille Toledo-Blass; Zeltzin Rivera-Herrera; Gustavo Guevara-Balcazar; Oscar Orihuela-Rodriguez; Jose A Morales-Carmona; Alexandre Kormanovski-Kovzova; Pedro Lopez-Sanchez; Ivan Rubio-Gayosso; Maria Del Carmen Castillo-Hernandez
Journal:  Pharmacol Res Perspect       Date:  2021-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.